Quick Answer
Bioventus Inc. reported Operating Income Loss of $53.98 million for the year ending 2025.
- Bioventus Inc. showed an increase of +455.2% in Operating Income Loss from 2024 to 2025.
- This data is from Bioventus Inc.'s annual report (Form 10-K), filed with the SEC on March 5, 2026.
- XBRL data for this metric is available from 2019 to 2025 (7 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2020: $12.99 million | Q2 2020: -$4.59 million | Q3 2020: $6.93 million | Q1 2021: $22.00 million | Q2 2021: -$5.74 million | Q3 2021: -$1.05 million | Q1 2022: -$21.45 million | Q2 2022: -$3.31 million | Q3 2022: -$126.84 million | Q1 2023: -$92.06 million | Q2 2023: $6.75 million | Q3 2023: $2.42 million | Q1 2024: $4.93 million | Q2 2024: -$31.47 million | Q3 2024: $3.65 million | Q1 2025: $4.87 million | Q2 2025: $18.37 million | Q3 2025: $11.25 million.
- Over the full 7 years of available data (2019 to 2025), Bioventus Inc.'s Operating Income Loss has grown by 73.0%.
- Historical annual values: Fiscal year 2025: $53.98 million | Fiscal year 2024: -$15.20 million | Fiscal year 2023: -$81.73 million | Fiscal year 2022: -$167.23 million | Fiscal year 2021: $12.06 million | Fiscal year 2020: $21.24 million | Fiscal year 2019: $31.19 million.
- Data sourced from SEC EDGAR public filings as of August 10, 2026.
Last verified: